United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News BlueWind Medical secures FDA clearance for enhanced Revi wearable as neuromodulation adoption shifts BlueWind Medical secures FDA clearance for an enhanced Revi wearable. Find out why adherence, not efficacy, is shaping neuromodulation strategy. byPallavi MadhirajuDecember 16, 2025